Analyst Opinion on Mylan and Medicis Pharmaceutical - Acquisitions and Approvals Abound in Generic Drug Industry
November 28 2012 - 8:00AM
Marketwired
The drugs - generic industry, within which
Mylan
Inc. (NASDAQ: MYL) and
Medicis Pharmaceutical
Corporation (NYSE: MRX) evolve, has been bustling with
activity recently. Several companies have had their generic
equivalents approved by the FDA while others have been involved in
mergers and acquisitions.
www.WallStreetActive.com is unswerving when it comes to teaching
the new and pro traders on how to take the helm in a market
environment that has been seeing waves upon waves of changes and
reap the rewards of participating in various sectors. We invite
serious traders to join our financial community so that they can
benefit from our free analytical coverage on Mylan and Medicis
Pharmaceutical by signing up at
http://www.wallstreetactive.com/
On the approval side of things, Mylan has been busy. The company
recently stated that, through one of its subsidiaries, it has
received final approval from the FDA for its generic version of
Pfizer's Revatio®. The company also has 172 Abbreviated New Drug
Applications awaiting FDA approval, including a number of potential
first-to-file applications. Analyst opinion on Mylan Inc.
accessible for free at
http://www.wallstreetactive.com/MYL28November12.pdf
Merger and acquisition activities have been robust in the
industry, as acquisitions cut out lengthy and expensive research
and development and instantly bolster product portfolios. Medicis
is one step closer to being acquired by Valeant Pharmaceuticals
International, as the U.S. Federal Trade Commission recently
completed its review of the potential acquisition and granted early
termination of the waiting period without conditions. The
acquisition still needs to be approved by Medicis' stockholders.
See what our analysts have to say on Medicis Pharmaceutical
Corporation. Follow the Link below
http://www.wallstreetactive.com/MRX28November12.pdf
About Wall Street Active: Wall Street
Active offers topmost independent research and investment
strategies with the sole purpose of consistently identifying stocks
that provide the biggest return on investment for our subscribers.
We provide sharp North American stock investing opinion with a
truly outstanding success rate. Our goal is for likeminded traders
to make a lot of money through our information.
Read our Disclaimer
http://www.wallstreetactive.com/disclaimer.html
Contact Person: Ravi S. Kapur Telecommunication,
Information & Data Manager info@wallstreetactive.com
Medicis (NYSE:MRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Medicis (NYSE:MRX)
Historical Stock Chart
From Oct 2023 to Oct 2024